These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19089768)

  • 1. Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth.
    Calda P
    J Matern Fetal Neonatal Med; 2009 Jun; 22(6):540-2. PubMed ID: 19089768
    [No Abstract]   [Full Text] [Related]  

  • 2. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F; Vaccaro V
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing preterm births.
    Reprod Biomed Online; 2007 May; 14(5):663. PubMed ID: 17509212
    [No Abstract]   [Full Text] [Related]  

  • 5. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    O'Brien JM
    Obstet Gynecol; 2012 Feb; 119(2 Pt 1):384-5; author reply 385-6. PubMed ID: 22270303
    [No Abstract]   [Full Text] [Related]  

  • 6. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens.
    O'Brien JM
    Ultrasound Obstet Gynecol; 2013 Sep; 42(3):247-53. PubMed ID: 23495199
    [No Abstract]   [Full Text] [Related]  

  • 8. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS; Brent RL; Calda P
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is in a name? A higher cost!
    Hansen KA
    S D Med; 2011 Jun; 64(6):194-5. PubMed ID: 21710803
    [No Abstract]   [Full Text] [Related]  

  • 10. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P; Stahl B; Klinger G
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
    O'Brien JM; Ho SJ; Istwan NB; Stanziano GJ; Rhea DJ; Barton JR
    Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey.
    Ness A; Dias T; Damus K; Burd I; Berghella V
    Am J Obstet Gynecol; 2006 Oct; 195(4):1174-9. PubMed ID: 17000251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestogen safety in multiple gestations: application of the Bradford Hill criteria.
    O'Brien JM
    BJOG; 2015 Apr; 122(5):610-4. PubMed ID: 25586892
    [No Abstract]   [Full Text] [Related]  

  • 14. Betamethasone compared with dexamethasone for preterm birth: a call for trials.
    Murphy KE
    Obstet Gynecol; 2007 Jul; 110(1):7-9. PubMed ID: 17601889
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
    O'Brien JM
    Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progestational agents for the prevention of preterm birth.
    Lamont RF; Jayasooriya GS
    J Perinat Med; 2009; 37(1):12-4. PubMed ID: 18999914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies.
    O'Brien JM; Lewis DF
    J Reprod Med; 2009 Feb; 54(2):73-87. PubMed ID: 19301570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should.
    O'Brien JM
    Am J Obstet Gynecol; 2011 May; 204(5):e16-7; author reply e17. PubMed ID: 21276949
    [No Abstract]   [Full Text] [Related]  

  • 19. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
    Combs CA; Garite T; Maurel K; Das A; Porto M;
    Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone and preterm birth.
    O'Brien JM
    N Engl J Med; 2007 Nov; 357(22):2306; author reply 2307. PubMed ID: 18050514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.